Hengrui Medicine (600276.SH) signs an authorization licensing agreement for the Rhucin Trastuzumab Project and is eligible to receive a maximum of $1.093 billion in milestone payments.

Zhixin Finance and Economics APP News: Hengrui Medicine (600276.SH) released an announcement, stating that the company has reached an agreement with Glenmark Specialty S.A. (referred to as "Glenmark Specialty") to license the company's independently developed innovative drug, SHR-A1811, a type 1 novel drug, to Glenmark Specialty for compensation.